1
|
Trujillo Cubillo L, Gurdal M, Zeugolis DI. Corneal fibrosis: From in vitro models to current and upcoming drug and gene medicines. Adv Drug Deliv Rev 2024; 209:115317. [PMID: 38642593 DOI: 10.1016/j.addr.2024.115317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 02/29/2024] [Accepted: 04/18/2024] [Indexed: 04/22/2024]
Abstract
Fibrotic diseases are characterised by myofibroblast differentiation, uncontrolled pathological extracellular matrix accumulation, tissue contraction, scar formation and, ultimately tissue / organ dysfunction. The cornea, the transparent tissue located on the anterior chamber of the eye, is extremely susceptible to fibrotic diseases, which cause loss of corneal transparency and are often associated with blindness. Although topical corticosteroids and antimetabolites are extensively used in the management of corneal fibrosis, they are associated with glaucoma, cataract formation, corneoscleral melting and infection, imposing the need of far more effective therapies. Herein, we summarise and discuss shortfalls and recent advances in in vitro models (e.g. transforming growth factor-β (TGF-β) / ascorbic acid / interleukin (IL) induced) and drug (e.g. TGF-β inhibitors, epigenetic modulators) and gene (e.g. gene editing, gene silencing) therapeutic strategies in the corneal fibrosis context. Emerging therapeutical agents (e.g. neutralising antibodies, ligand traps, receptor kinase inhibitors, antisense oligonucleotides) that have shown promise in clinical setting but have not yet assessed in corneal fibrosis context are also discussed.
Collapse
Affiliation(s)
- Laura Trujillo Cubillo
- Regenerative, Modular & Developmental Engineering Laboratory (REMODEL), Charles Institute of Dermatology, Conway Institute of Biomolecular & Biomedical Research and School of Mechanical & Materials Engineering, University College Dublin (UCD), Dublin, Ireland
| | - Mehmet Gurdal
- Regenerative, Modular & Developmental Engineering Laboratory (REMODEL), Charles Institute of Dermatology, Conway Institute of Biomolecular & Biomedical Research and School of Mechanical & Materials Engineering, University College Dublin (UCD), Dublin, Ireland
| | - Dimitrios I Zeugolis
- Regenerative, Modular & Developmental Engineering Laboratory (REMODEL), Charles Institute of Dermatology, Conway Institute of Biomolecular & Biomedical Research and School of Mechanical & Materials Engineering, University College Dublin (UCD), Dublin, Ireland.
| |
Collapse
|
2
|
Posarelli M, Romano D, Tucci D, Giannaccare G, Scorcia V, Taloni A, Pagano L, Borgia A. Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art. BIOTECH 2023; 12:48. [PMID: 37366796 DOI: 10.3390/biotech12020048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 06/10/2023] [Accepted: 06/13/2023] [Indexed: 06/28/2023] Open
Abstract
The ocular surface is a complex structure that includes cornea, conjunctiva, limbus, and tear film, and is critical for maintaining visual function. When the ocular-surface integrity is altered by a disease, conventional therapies usually rely on topical drops or tissue replacement with more invasive procedures, such as corneal transplants. However, in the last years, regeneration therapies have emerged as a promising approach to repair the damaged ocular surface by stimulating cell proliferation and restoring the eye homeostasis and function. This article reviews the different strategies employed in ocular-surface regeneration, including cell-based therapies, growth-factor-based therapies, and tissue-engineering approaches. Dry eye and neurotrophic keratopathy diseases can be treated with nerve-growth factors to stimulate the limbal stem-cell proliferation and the corneal nerve regeneration, whereas conjunctival autograft or amniotic membrane are used in subjects with corneal limbus dysfunction, such as limbal stem-cell deficiency or pterygium. Further, new therapies are available for patients with corneal endothelium diseases to promote the expansion and migration of cells without the need of corneal keratoplasty. Finally, gene therapy is a promising new frontier of regeneration medicine that can modify the gene expression and, potentially, restore the corneal transparency by reducing fibrosis and neovascularization, as well as by stimulating stem-cell proliferation and tissue regeneration.
Collapse
Affiliation(s)
- Matteo Posarelli
- St. Paul's Eye Unit, Department of Corneal Diseases, Royal Liverpool University Hospital, Liverpool L7 8YE, UK
- Ophthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy
| | - Davide Romano
- Eye Clinic, Department of Neurological and Vision Sciences, University of Brescia, 25123 Brescia, Italy
- Eye Unit, University Hospitals of Leicester, NHS Trust, Leicester LE1 5WW, UK
| | - Davide Tucci
- Department of Biomedical and Surgical Sciences, Section of Ophthalmology, S. Maria Della Misericordia Hospital, University of Perugia, 06123 Perugia, Italy
| | - Giuseppe Giannaccare
- Department of Ophthalmology, University Magna Græcia of Catanzaro, 88100 Catanzaro, Italy
| | - Vincenzo Scorcia
- Department of Ophthalmology, University Magna Græcia of Catanzaro, 88100 Catanzaro, Italy
| | - Andrea Taloni
- Department of Ophthalmology, University Magna Græcia of Catanzaro, 88100 Catanzaro, Italy
| | - Luca Pagano
- St. Paul's Eye Unit, Department of Corneal Diseases, Royal Liverpool University Hospital, Liverpool L7 8YE, UK
| | - Alfredo Borgia
- St. Paul's Eye Unit, Department of Corneal Diseases, Royal Liverpool University Hospital, Liverpool L7 8YE, UK
- Eye Unit, Humanitas-Gradenigo Hospital, 10153 Turin, Italy
| |
Collapse
|
3
|
Amador C, Shah R, Ghiam S, Kramerov AA, Ljubimov AV. Gene therapy in the anterior eye segment. Curr Gene Ther 2021; 22:104-131. [PMID: 33902406 DOI: 10.2174/1566523221666210423084233] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 03/14/2021] [Accepted: 04/04/2021] [Indexed: 11/22/2022]
Abstract
This review provides comprehensive information about the advances in gene therapy in the anterior segment of the eye including cornea, conjunctiva, lacrimal gland, and trabecular meshwork. We discuss gene delivery systems including viral and non-viral vectors as well as gene editing techniques, mainly CRISPR-Cas9, and epigenetic treatments including antisense and siRNA therapeutics. We also provide a detailed analysis of various anterior segment diseases where gene therapy has been tested with corresponding outcomes. Disease conditions include corneal and conjunctival fibrosis and scarring, corneal epithelial wound healing, corneal graft survival, corneal neovascularization, genetic corneal dystrophies, herpetic keratitis, glaucoma, dry eye disease, and other ocular surface diseases. Although most of the analyzed results on the use and validity of gene therapy at the ocular surface have been obtained in vitro or using animal models, we also discuss the available human studies. Gene therapy approaches are currently considered very promising as emerging future treatments of various diseases, and this field is rapidly expanding.
Collapse
Affiliation(s)
- Cynthia Amador
- Eye Program, Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States
| | - Ruchi Shah
- Eye Program, Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States
| | - Sean Ghiam
- Sackler School of Medicine, New York State/American Program of Tel Aviv University, Tel Aviv, Israel
| | - Andrei A Kramerov
- Eye Program, Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States
| | - Alexander V Ljubimov
- Eye Program, Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States
| |
Collapse
|
4
|
Singh RK, Binette F, Seiler M, Petersen-Jones SM, Nasonkin IO. Pluripotent Stem Cell-Based Organoid Technologies for Developing Next-Generation Vision Restoration Therapies of Blindness. J Ocul Pharmacol Ther 2021; 37:147-156. [PMID: 33052761 PMCID: PMC8060716 DOI: 10.1089/jop.2020.0016] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Accepted: 07/28/2020] [Indexed: 12/25/2022] Open
Abstract
Blindness, associated with death of retinal cells at the back of the eye, is caused by a number of conditions with high prevalence such as glaucoma, age-related macular degeneration, and diabetic retinopathy. In addition, a large number of orphan inherited (mostly monogenic) conditions, such as retinitis pigmentosa and Leber Congenital Amaurosis, add to the overall number of patients with blinding retinal degenerative diseases. Blindness caused by deterioration and loss of retina is so far incurable. Modern biomedical research leveraging molecular and regenerative medicine approaches had a number of groundbreaking discoveries and proof-of-principle treatments of blindness in animals. However, these methods are slow to be standardized and commercialized as therapies to benefit people losing their eyesight due to retinal degenerative conditions. In this review, we will outline major regenerative medicine approaches, which are emerging as promising for preserving or/and restoring vision. We discuss the potential of each of these approaches to reach commercialization step and be converted to treatments, which could at least ameliorate blindness caused by retinal cell death.
Collapse
Affiliation(s)
| | | | - Magdalene Seiler
- Stem Cell Research Center, University of California, Irvine, Irvine, California, USA
- Department of Physical Medicine & Rehabilitation, University of California, Irvine, Irvine, California, USA
- Department of Ophthalmology, University of California, Irvine, Irvine, California, USA
- Department of Anatomy & Neurobiology, University of California, Irvine, Irvine, California, USA
| | - Simon M. Petersen-Jones
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA
| | | |
Collapse
|
5
|
Molaei A, Abedloo E, de Smet MD, Safi S, Khorshidifar M, Ahmadieh H, Khosravi MA, Daftarian N. Toward the Art of Robotic-assisted Vitreoretinal Surgery. J Ophthalmic Vis Res 2017; 12:212-218. [PMID: 28540014 PMCID: PMC5423376 DOI: 10.4103/jovr.jovr_63_17] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
New technological progress in robotics has brought many beneficial clinical applications. Currently, computer integrated robotic surgery has gained clinical acceptance for several surgical procedures. Robotically assisted eye surgery is envisaged as a promising solution to overcome the shortcomings inherent to conventional surgical procedures as in vitreoretinal surgeries. Robotics by its high precision and fine mechanical control can improve dexterity, cancel tremor, and allow highly precise remote surgical capability, delicate vitreoretinal manipulation capabilities. Combined with magnified three-dimensional imaging of the surgical site, it can enhance surgical precision. Tele-manipulation can provide the ability for tele-surgery or haptic feedback of forces generated by the manipulation of intraocular tissues. It presents new solutions for some sight-threatening conditions such as retinal vein cannulation where, due to physiological limitations of the surgeon's hand, the procedure cannot be adequately performed. In this paper, we provide an overview of the research and advances in robotically assisted vitreoretinal eye surgery. Additionally the barriers to the integration of this method in the field of ocular surgery are summarized. Finally, we discuss the possible applications of the method in the area of vitreoretinal surgery.
Collapse
Affiliation(s)
- Amir Molaei
- Department of Electrical Engineering, K.N Toosi University of Technology, Tehran, Iran.,Department of Mechanical Engineering, Concordia University, Montreal, Canada
| | - Ebrahim Abedloo
- Department of Electrical Engineering, K.N Toosi University of Technology, Tehran, Iran
| | - Marc D de Smet
- MicroInvasive Ocular Surgery Center (MIOS sa), Lausanne, Switzerland.,Preceyes bv, Eindhoven, the Netherlands
| | - Sare Safi
- Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Milad Khorshidifar
- Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Hamid Ahmadieh
- Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | - Narsis Daftarian
- Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.,Ocular Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
6
|
Abstract
Up to 15 years ago, bibliographic searches based on keywords such as “photoreceptor degeneration, inner retina” or “photoreceptor degeneration, second order neurons” returned only a handful of papers, as the field was dominated by the general assumption that retinal degeneration had direct effects on the sole populations of rods and cones. Since then, a number of studies have been dedicated to understanding the process of gradual morphological, molecular, and functional changes arising among cells located in the inner retina (comprising neurons, glia, and blood vessels), that is to say “beyond” photoreceptors. General aspects of this progression of biological rearrangements, now referred to as “remodeling”, were revealed and demonstrated to accompany consistently photoreceptor loss, independently from the underlying cause of degeneration. Recurrent features of remodeling are summarized here, to provide a general frame for to the various analytical descriptions and reviews contributed by the articles in the issue (among others, see Euler and Schubert, 2015; Soto and Kerschensteiner, 2015, this issue).
Collapse
Affiliation(s)
- Enrica Strettoi
- Italian National Research Council, Neuroscience Institute Pisa, Italy
| |
Collapse
|
7
|
Ueyama K, Mori K, Shoji T, Omata H, Gehlbach PL, Brough DE, Wei LL, Yoneya S. Ocular localization and transduction by adenoviral vectors are serotype-dependent and can be modified by inclusion of RGD fiber modifications. PLoS One 2014; 9:e108071. [PMID: 25232844 PMCID: PMC4169476 DOI: 10.1371/journal.pone.0108071] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2014] [Accepted: 08/24/2014] [Indexed: 11/18/2022] Open
Abstract
Purpose To evaluate localization and transgene expression from adenoviral vector of serotypes 5, 35, and 28, ± an RGD motif in the fiber following intravitreal or subretinal administration. Methods Ocular transduction by adenoviral vector serotypes ± RGD was studied in the eyes of mice receiving an intravitreous or subretinal injection. Each serotype expressed a CMV-GFP expression cassette and histological sections of eyes were examined. Transgene expression levels were examined using luciferase (Luc) regulated by the CMV promoter. Results GFP localization studies revealed that serotypes 5 and 28 given intravitreously transduced corneal endothelial, trabecular, and iris cells. Intravitreous delivery of the unmodified Ad35 serotype transduced only trabecular meshwork cells, but, the modification of the RGD motif into the fiber of the Ad35 viral vector base expanded transduction to corneal endothelial and iris cells. Incorporation of the RGD motif into the fiber knob with deletion of RGD from the penton base did not affect the transduction ability of the Ad5 vector base. Subretinal studies showed that RGD in the Ad5 knob shifted transduction from RPE cells to photoreceptor cells. Using a CMV-Luc expression cassette, intravitreous delivery of all the tested vectors, such as Ad5-, Ad35- and Ad28- resulted in an initial rapid induction of luciferase activity that thereafter declined. Subretinal administration of vectors showed a marked difference in transgene activity. Ad35-Luc gene expression peaked at 7 days and remained elevated for 6 months. Ad28-Luc expression was high after 1 day and remained sustained for one month. Conclusions Different adenoviral vector serotypes ± modifications transduce different cells within the eye. Transgene expression can be brief or extended and is serotype and delivery route dependent. Thus, adenoviral vectors provide a versatile platform for the delivery of therapeutic agents for ocular diseases.
Collapse
Affiliation(s)
- Kazuhiro Ueyama
- Department of Ophthalmology, Saitama Medical University, Moroyama, Iruma, Saitama, Japan
- * E-mail:
| | - Keisuke Mori
- Department of Ophthalmology, Saitama Medical University, Moroyama, Iruma, Saitama, Japan
| | - Takuhei Shoji
- Department of Ophthalmology, Saitama Medical University, Moroyama, Iruma, Saitama, Japan
| | - Hidekazu Omata
- Department of Ophthalmology, Saitama Medical University, Moroyama, Iruma, Saitama, Japan
| | - Peter L. Gehlbach
- Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
| | | | - Lisa L. Wei
- GenVec, Inc., Gaithersburg, Maryland, United States of America
- National Eye Institute, Bethesda, Maryland, United States of America
| | - Shin Yoneya
- Department of Ophthalmology, Saitama Medical University, Moroyama, Iruma, Saitama, Japan
| |
Collapse
|
8
|
Swaminathan SS, Oh DJ, Kang MH, Shepard AR, Pang IH, Rhee DJ. TGF-β2-mediated ocular hypertension is attenuated in SPARC-null mice. Invest Ophthalmol Vis Sci 2014; 55:4084-97. [PMID: 24906856 DOI: 10.1167/iovs.13-12463] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
PURPOSE Transforming growth factor-β2 (TGF-β2) has been implicated in the pathogenesis of primary open-angle glaucoma through extracellular matrix (ECM) alteration among various mechanisms. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein that regulates ECM within the trabecular meshwork (TM), and is highly upregulated by TGF-β2. We hypothesized that, in vivo, SPARC is a critical regulatory node in TGF-β2-mediated ocular hypertension. METHODS Empty (Ad.empty) or TGF-β2-containing adenovirus (Ad.TGF-β2) was injected intravitreally into C57BL6-SV129 WT and SPARC-null mice. An initial study was performed to identify a stable period for IOP measurement under isoflurane. The IOP was measured before injection and every other day for two weeks using rebound tonometry. Additional mice were euthanized at peak IOP for immunohistochemistry. RESULTS The IOP was stable under isoflurane during minutes 5 to 8. The IOP was significantly elevated in Ad.TGF-β2-injected (n = 8) versus Ad.empty-injected WT (n = 8) mice and contralateral uninjected eyes during days 4 to 11 (P < 0.03). The IOPs were not significantly elevated in Ad.TGF-β2-injected versus Ad.empty-injected SPARC-null mice. However, on day 8, the IOP of Ad.TGF-β2-injected SPARC-null eyes was elevated compared to that of contralateral uninjected eyes (P = 0.0385). Immunohistochemistry demonstrated that TGF-β2 stimulated increases in collagen IV, fibronectin, plasminogen activator inhibitor-1 (PAI-1), connective tissue growth factor (CTGF), and SPARC in WT mice, but only PAI-1 and CTGF in SPARC-null mice (P < 0.05). CONCLUSIONS SPARC is essential to the regulation of TGF-β2-mediated ocular hypertension. Deletion of SPARC significantly attenuates the effects of TGF-β2 by restricting collagen IV and fibronectin expression. These data provide further evidence that SPARC may have an important role in IOP regulation and possibly glaucoma pathogenesis.
Collapse
Affiliation(s)
- Swarup S Swaminathan
- Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
| | - Dong-Jin Oh
- Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
| | - Min Hyung Kang
- Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
| | - Allan R Shepard
- Ophthalmology Research/Glaucoma Research, Novartis Institutes for Biomedical Research, Fort Worth, Texas, United States
| | - Iok-Hou Pang
- Department of Pharmaceutical Sciences and North Texas Eye Research Institute, University of North Texas Health Sciences Center, Fort Worth, Texas, United States
| | - Douglas J Rhee
- Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
| |
Collapse
|
9
|
Igarashi T, Miyake K, Asakawa N, Miyake N, Shimada T, Takahashi H. Direct comparison of administration routes for AAV8-mediated ocular gene therapy. Curr Eye Res 2013; 38:569-77. [PMID: 23489150 DOI: 10.3109/02713683.2013.779720] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
PURPOSE We recently demonstrated that direct subretinal (SR) injection of adeno-associated virus (AAV) type 8 (AAV8) into photoreceptor cells and retinal pigment epithelium (RPE) is a highly efficient model of gene delivery. The current study compared transduction efficiency and expression patterns associated with various routes of vector administration. METHOD The efficacy of intravitreal (VT), SR and subconjunctival (SC) injections for delivery of AAV8-derived vectors, i.e. those expressing luciferase (Luc) and enhanced green fluorescent protein (GFP) - AAV8/Luc and AAV8/GFP, respectively - were compared in an animal (mouse) model (n = 8 mice/group). Transduction efficiency and expression patterns were examined at post-injection weeks 1 and 2, and months 1, 3, 6 and 12 via in vivo imaging. RESULTS One year after AAV injection, AAV8/Luc-treated mice exhibited stable and sustained high expression of vector in the VT and SR groups, but not in the SC group (VT:SR:SC = 3,218:2,923:115; 1 × 10(5 )photons/s). Histological analysis showed that GFP expression was observed in the inner retina of VT group mice, and in photoreceptor cells and RPE of SR group mice, whereas no GFP expression was noted in the SC group. Electroretinography (ERG) revealed adverse effects following SR delivery. CONCLUSIONS Results suggest that both SR and VT injections of AAV8 vectors are useful routes for administering ocular gene therapy, and stress the importance of selecting an appropriate administration route, i.e. one that targets specific cells, for treating ocular disorders.
Collapse
Affiliation(s)
- Tsutomu Igarashi
- Department of Ophthalmology, Nippon Medical School, Tokyo, Japan.
| | | | | | | | | | | |
Collapse
|
10
|
Park HYL, Kim JH, Sun Kim H, Park CK. Stem cell-based delivery of brain-derived neurotrophic factor gene in the rat retina. Brain Res 2012; 1469:10-23. [PMID: 22750585 DOI: 10.1016/j.brainres.2012.06.006] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2011] [Revised: 05/18/2012] [Accepted: 06/06/2012] [Indexed: 12/28/2022]
Abstract
As an alternative to a viral vector, the application of stem cells to transfer specific genes is under investigation in various organs. Using this strategy may provide more effective method to supply neurotrophic factor to the neurodegenerative diseases caused by neurotrophic factor deprivation. This study investigated the possibility and efficacy of stem cell-based delivery of the brain-derived neurotrophic factor (BDNF) gene to rat retina. Rat BDNF cDNA was transduced into rat bone marrow mesenchymal stem cells (rMSCs) using a retroviral vector. Its incorporation into the experimental rat retina and the expression of BDNF after intravitreal injection or subretinal injection were detected by real-time PCR, western blot analysis, and immunohistochemical staining. For the incorporated rMSCs, retinal-specific marker staining was performed to investigate the changes in morphology and the characteristics of the stem cells. Transduction of the rMSCs by retrovirus was effective, and the transduced rMSCs expressed high levels of the BDNF gene and protein. The subretinal injection of rMSCs produced rMSC migration and incorporation into the rat retina (about 15.7% incorporation rate), and retinal BDNF mRNA and protein expression was increased at 4 weeks after transplantation. When subretinal injection of rMSCs was applied to axotomized rat retina, it significantly increased the expression of BDNF until 4 weeks after transplantation. Some of the transplanted rMSCs exhibited morphological changes, but the retinal-specific marker stain was not sufficient to indicate whether neuronal differentiation had occurred. Using mesenchymal stem cells to deliver the BDNF gene to the retina may provide new treatment for glaucoma.
Collapse
Affiliation(s)
- Hae-Young Lopilly Park
- Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Seocho-ku, Seoul 137-701, Republic of Korea
| | | | | | | |
Collapse
|
11
|
Abstract
Despite new and improving diagnostic and therapeutic options for glaucoma, blindness from glaucoma is increasing and glaucoma remains a major public health problem. The role of heredity in ocular disease including glaucoma is attracting greater attention as the knowledge and recent advances of Human Genome Project and the HapMap Project have made genetic analysis of many human disorders possible.Glaucoma offers a variety of potential targets for gene therapy. All risk factors for glaucoma and their underlying causes are potentially susceptible to modulation by gene transfer. As genetic defects responsible for glaucoma are identified and the biochemical mechanisms underlying the disease are recognized, new methods of therapy can be developed. Genetic tests are indicated for treatment, diagnosis, prognosis, counseling, and research purposes; however, there is significant overlap among them. One of the important genetic tests for glaucoma is OcuGene. Therefore, it is of utmost importance for the glaucoma specialists to be familiar with and understand the basic molecular mechanisms, genes responsible for glaucoma, and the ways of genetic treatment.Recently, several promising genetic therapeutic approaches had been investigated. Some are either used to stop apoptosis and halt further glaucomatous damage, wound healing modulating effect or long lasting intraocular pressure lowering effects than the conventional commercially available antiglaucoma medications. METHOD OF LITERATURE SEARCH: The literature was searched on the Medline database using the PubMed interface. The key words for search were glaucoma, gene therapy, and genetic diagnosis of glaucoma.
Collapse
Affiliation(s)
- Mohamed Abdel-Monem Soliman Mahdy
- Department of Ophthalmology, Rustaq Hospital, Rustaq, Sultanate of Oman and Al-Hussein University Hospital, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
| |
Collapse
|
12
|
Igarashi T, Miyake K, Masuda I, Takahashi H, Shimada T. Adeno-associated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model. Hum Gene Ther 2010; 21:631-7. [PMID: 20053138 DOI: 10.1089/hum.2009.153] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
To assess the feasibility of a gene therapeutic approach to treating choroidal neovascularization (CNV), we generated a recombinant adeno-associated viral (AAV) vector (type 8) encoding soluble Flt-1 (AAV-sflt-1), and determined its ability to inhibit angiogenesis. When we treated human umbilical vein endothelial cells (HUVECs) with the supernatant of cells transduced with AAV-sflt-1 or AAV-EGFP (control), we found that tube formation was significantly inhibited by the former but not the latter (area: 25,121 +/- 557 vs. 68,628 +/- 1357 pixels [p < 0.01]; length: 4811 +/- 246 vs. 10,894 +/- 297 pixels [p < 0.01]). CNV was induced in C57BL/6 mice by making four separate choroidal burns around the optic nerve in each eye, using a diode laser. Thereafter, 2 microl (5 x 10(11) vector genomes/ml) of AAV-sflt-1 (n = 11) or control AAV-LacZ (n = 12) was injected into the subretinal space, and 2 weeks later the eyes were removed for flatmount analysis of CNV surface area. Notably, subretinal delivery of AAV-sflt-1 significantly diminished CNV at the laser lesions, as compared with AAV-LacZ (555 +/- 304 vs. 1470 +/- 1000 microm(2); p = 0.007). These results suggest that there was diffusion of the secreted sFlt-1 across the retina and that long-term suppression of CNV is possible through the use of stable rAAV-mediated sflt-1 expression. In vivo gene therapy thus appears to be a feasible approach to the clinical management of CNV in conditions such as age-related macular degeneration.
Collapse
Affiliation(s)
- Tsutomu Igarashi
- Department of Ophthalmology, Research Center for Advanced Medical Technology, Nippon Medical School, Bunkyo-ku, Tokyo 113-8603, Japan
| | | | | | | | | |
Collapse
|
13
|
|
14
|
Ultrasound-targeted microbubble destruction enhances AAV-mediated gene transfection in human RPE cells in vitro and rat retina in vivo. Gene Ther 2009; 16:1146-53. [PMID: 19571889 DOI: 10.1038/gt.2009.84] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
This study was conducted to investigate the efficacy and safety of ultrasound (US)-targeted microbubble (MB) destruction (UTMD)-mediated rAAV2-CMV-EGFP transfection to cultured human retinal pigment epithelium (RPE) cells in vitro and to the rat retina in vivo. In the in vitro study, cultured human RPE cells were exposed to US under different conditions with or without MBs. Furthermore, the effect of UTMD on rAAV2-CMV-EGFP itself and on cells was evaluated. In the in vivo study, gene transfer was examined by injecting rAAV2-CMV-EGFP into the subretinal space of rats with or without MBs and then exposed to US. We investigated enhanced green fluorescent protein (EGFP) expression in vivo by stereomicroscopy and performed quantitative analysis using Axiovision 3.1 software. Hematoxylin and eosin staining and frozen sections were used to observe tissue damage and location of the EGFP gene expression. In the in vitro study, the transfection efficiency of rAAV2-CMV-EGFP under optimal UTMD was significantly higher than that of the control group (P=0.000). Furthermore, there was almost no cytotoxicity to the cells and to rAAV2-CMV-EGFP itself. In the in vivo study, UTMD could be used safely to enhance and accelerate the transgene expression of the retina. Fluorescence expression was mainly located in the retinal layer. UTMD is a promising method for gene delivery to the retina.
Collapse
|
15
|
Wiggs JL. Fundamentals of Human Genetics. Ophthalmology 2009. [DOI: 10.1016/b978-0-323-04332-8.00001-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
16
|
Lebherz C, Maguire A, Tang W, Bennett J, Wilson JM. Novel AAV serotypes for improved ocular gene transfer. J Gene Med 2008; 10:375-82. [PMID: 18278824 DOI: 10.1002/jgm.1126] [Citation(s) in RCA: 142] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Some of the most successful gene therapy results have been obtained using recombinant viral vectors to treat animal models of inherited and acquired ocular diseases. Clinical trials using adenovirus vector systems have been initiated for two ocular diseases. Adeno-associated viruses (AAVs) represent an attractive alternative to adenoviral vector systems as they enable stable and long-term expression and can target a variety of different ocular cell types depending on the capsid serotype; recently clinical trails for congenital blindness was initiated with a vector-based AAV serotype 2. High levels of retinal gene transfer have been achieved using vectors based on AAV serotypes 1, 2, 4 and 5. This report compares the gene transfer efficacy and stability of expression of vector systems based on three novel AAV serotypes: AAV7, 8, 9, with the established vectors AAV1, 2, 5. We show here that AAV7 and 8 enable superior long-term transduction of retinal and also anterior chamber structures.
Collapse
Affiliation(s)
- Corinna Lebherz
- Gene Therapy Program, Division of Medical Genetics, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | | | | | | | | |
Collapse
|
17
|
Allocca M, Doria M, Petrillo M, Colella P, Garcia-Hoyos M, Gibbs D, Kim SR, Maguire A, Rex TS, Di Vicino U, Cutillo L, Sparrow JR, Williams DS, Bennett J, Auricchio A. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 2008; 118:1955-64. [PMID: 18414684 DOI: 10.1172/jci34316] [Citation(s) in RCA: 217] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2007] [Accepted: 02/29/2008] [Indexed: 12/23/2022] Open
Abstract
Vectors derived from adeno-associated virus (AAV) are promising for human gene therapy, including treatment for retinal blindness. One major limitation of AAVs as vectors is that AAV cargo capacity has been considered to be restricted to 4.7 kb. Here we demonstrate that vectors with an AAV5 capsid (i.e., rAAV2/5) incorporated up to 8.9 kb of genome more efficiently than 6 other serotypes tested, independent of the efficiency of the rAAV2/5 production process. Efficient packaging of the large murine Abca4 and human MYO7A and CEP290 genes, which are mutated in common blinding diseases, was obtained, suggesting that this packaging efficiency is independent of the specific sequence packaged. Expression of proteins of the appropriate size and function was observed following transduction with rAAV2/5 carrying large genes. Intraocular administration of rAAV2/5 encoding ABCA4 resulted in protein localization to rod outer segments and significant and stable morphological and functional improvement of the retina in Abca4(-/-) mice. This use of rAAV2/5 may be a promising therapeutic strategy for recessive Stargardt disease, the most common form of inherited macular degeneration. The possibility of packaging large genes in AAV greatly expands the therapeutic potential of this vector system.
Collapse
|
18
|
An empty E1, E3, E4 adenovirus vector protects photoreceptors from light-induced degeneration. J Ocul Biol Dis Infor 2008; 1:30-6. [PMID: 20072633 PMCID: PMC2802415 DOI: 10.1007/s12177-008-9004-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2008] [Accepted: 03/12/2008] [Indexed: 11/30/2022] Open
Abstract
We have previously identified a neuroprotective effect associated with empty (E1−, E3−, E4−) adenovirus vector delivery in a model of light-induced, photoreceptor cell death. In this study, we further characterize this protective effect in light-injured retina and investigate its molecular basis. Dark-adapted BALB/c mice, aged 6–8 weeks, were exposed to standardized, intense fluorescent light for 96 or 144 h. Prior to dark adaptation, all mice received intravitreous injection of 1 × 109 particles of an empty (E1−, E3−, E4−) adenovirus vector in one eye and vehicle in the other. Following light challenge of 96 or 144 h, histopathological analysis and quantitative photoreceptor cell counts were conducted. Semiquantitative assessment of messenger ribonucleic acid (mRNA) for the apoptosis related genes: p50, p65, IkBa, caspase-1, caspase-3, Bad, c-Jun, Bax, Bak, Bcl-2, c-Fos, and p53 using quantitative reverse transcriptase polymerase chain reaction was performed on eyes following 12 h of light exposure. Following 96 h of light exposure, the photoreceptor cell density for E1−, E3−, E4− adenovirus vector and vehicle-injected eyes were 87.5 ± 9.5 and 79.3 ± 10.1, respectively, (p = 0.79). After 144 h of light exposure, the photoreceptor cell density was preserved in vector-injected eyes as compared to vehicle treated eyes, 68.9 ± 10.0 and 49.2 ± 4.6, respectively (p = 0.016). Relative mRNA levels of c-Fos and c-Jun at 12-h light exposure after injection differed significantly between vector- and vehicle-injected eyes (p = 0.036, 0.016, respectively). The expression of the other apoptosis-related genes evaluated was not significantly affected. This study investigates the molecular basis of photoreceptor neuroprotective pathway induction associated with E1−, E3−, E4− adenovirus vectors. The results indicate that empty adenovirus vectors protect photoreceptors from light-induced degeneration by the modulation of apoptotic pathways. Gene expression changes suggest that the suppression of c-Fos and c-Jun upregulation contributes significantly to the neuroprotective effect. Understanding the molecular basis of the neuroprotective pathway induction in photoreceptors is critical to the development of novel therapies for retinal degenerations.
Collapse
|
19
|
Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther 2008; 15:668-76. [PMID: 18305575 DOI: 10.1038/gt.2008.16] [Citation(s) in RCA: 118] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Gene transfer is considered to be a promising alternative for the treatment of several chronic diseases that affect the ocular surface. The goal of the present work was to investigate the efficacy and mechanism of action of a novel DNA nanocarrier made of hyaluronan (HA) and chitosan (CS), specifically designed for topical ophthalmic gene therapy. With this goal in mind, we first evaluated the transfection efficiency of the plasmid DNA-loaded nanoparticles in a human corneal epithelium cell model. Second, we investigated the bioadhesion and internalization of the nanoparticles in the rabbit ocular epithelia by confocal laser scanning microscopy. Third, we determined the in vivo efficacy of these nanocarriers in terms of their ability to transfect ocular tissues. The results showed that HA-CS nanoparticles and, in particular, those made of low molecular weight CS (10-12 kDa), led to high levels of expression of secreted alkaline phosphatase in the human corneal epithelium model. In addition, we observed that, following topical administration to rabbits, these nanoparticles entered the corneal and conjunctival epithelial cells and, then, become assimilated by the cells. More importantly, these nanoparticles provided an efficient delivery of the associated plasmid DNA inside the cells, reaching significant transfection levels. Therefore, we conclude that these nanoparticles may represent a new strategy toward the gene therapy of several ocular diseases.
Collapse
|
20
|
Surace EM, Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vision Res 2008; 48:353-9. [DOI: 10.1016/j.visres.2007.07.027] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2007] [Revised: 07/31/2007] [Accepted: 07/31/2007] [Indexed: 12/21/2022]
|
21
|
Lamartina S, Cimino M, Roscilli G, Dammassa E, Lazzaro D, Rota R, Ciliberto G, Toniatti C. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. J Gene Med 2007; 9:862-74. [PMID: 17685494 DOI: 10.1002/jgm.1083] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND Ocular neovascular disorders, such as diabetic retinopathy and age-related macular degeneration, are the principal causes of blindness in developed countries. Current treatments are of limited efficacy, whereas a therapy based on intraocular gene transfer of angiostatic factors represents a promising alternative. For the first time we have explored the potential of helper-dependent adenovirus (HD-Ad), the last generation of Ad vectors, in the therapy of retinal neovascularization. METHODS We first analyzed efficiency and stability of intraretinal gene transfer following intravitreous injection in mice. A HD-Ad vector expressing green fluorescent protein (GFP) under the control of the cytomegalovirus (CMV) promoter (HD-Ad/GFP) was compared with a first-generation (E1/E3-deleted) Ad vector carrying an identical GFP expression cassette (FG-Ad/GFP). We also constructed HD-Ad vectors expressing a soluble form of the VEGF receptor (sFlt-1) in a constitutive (HD-Ad/sFlt-1) or doxycycline (dox)-inducible (HD-Ad/S-M2/sFlt-1) manner and tested their therapeutic efficacy upon intravitreous delivery in a rat model of oxygen-induced retinopathy (OIR). RESULTS HD-Ad/GFP promoted long-lasting (up to 1 year) transgene expression in retinal Müller cells, in marked contrast with the short-term expression observed with FG-Ad/GFP. Intravitreous injection of HD-Ad vectors expressing sFlt-1 resulted in detectable levels of sFlt-1 and inhibited retinal neovascularization by more than 60% in a rat model of OIR. Notably, the therapeutic efficacy of the inducible vector HD-Ad/S-M2/sFlt-1 was strictly dox-dependent. CONCLUSIONS HD-Ad vectors enable stable gene transfer and regulated expression of angiostatic factors following intravitreous injection and thus are attractive vehicles for the gene therapy of neovascular diseases of the retina.
Collapse
|
22
|
Khare PD, Loewen N, Teo W, Barraza RA, Saenz DT, Johnson DH, Poeschla EM. Durable, safe, multi-gene lentiviral vector expression in feline trabecular meshwork. Mol Ther 2007; 16:97-106. [PMID: 17912236 DOI: 10.1038/sj.mt.6300318] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Multiple disease-specific considerations have led to interest in the potential of gene therapy to permanently correct elevated intraocular pressure (IOP), the main causal risk factor for primary open angle glaucoma (POAG). Since IOP elevation results from abnormal resistance to aqueous humor outflow from the eye through the trabecular meshwork (TM), a means to genetically modify this specialized outflow organ permanently and safely is a prioritized goal. Here we tested different lentiviral vector designs and doses for long-term transgene expression in a large animal model, and investigated whether exogenously introduced myocilin proteins influenced IOP. The anterior chambers of 18 domestic cats (36 eyes) were injected with dual-gene feline immunodeficiency virus (FIV) vectors. Substantial, well-tolerated green fluorescent protein (GFP) expression was achieved in TM and monitored non-invasively in vivo for 1.2-2.3 years, using both 5' cap-translation and internal ribosome entry site (IRES)-translation. In all 36 eyes, post-mortem examination revealed substantial TM transgene expression (which often greatly exceeded that observable non-invasively during life). However, co-expression with enhanced GFP of myocilin or a juvenile glaucoma-associated mutant myocilin did not elevate IOP. These results demonstrate a safe, long-term single and dual gene expression in TM and establish an experimental system for testing candidate therapeutic transgenes for POAG.
Collapse
Affiliation(s)
- Pranay D Khare
- 1Molecular Medicine Program; Mayo Clinic College of Medicine, Rochester, Minnesota, USA
| | | | | | | | | | | | | |
Collapse
|
23
|
Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV. Corneal gene therapy. J Control Release 2007; 124:107-33. [PMID: 17707107 DOI: 10.1016/j.jconrel.2007.05.041] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2007] [Accepted: 05/15/2007] [Indexed: 12/23/2022]
Abstract
Gene therapy to the cornea can potentially correct inherited and acquired diseases of the cornea. Factors that facilitate corneal gene delivery are the accessibility and transparency of the cornea, its stability ex vivo and the immune privilege of the eye. Initial corneal gene delivery studies characterized the relationship between intraocular modes of administration and location of reporter gene expression. The challenge of achieving effective topical gene transfer, presumably due to tear flow, blinking and low penetration of the vector through epithlelial tight junctions left no alternative but invasive administration to the anterior chamber and corneal stroma. DNA vaccination, RNA interference and gene transfer of cytokines, growth factors and enzymes modulated the corneal microenvironment. Positive results were obtained in preclinical studies for prevention and treatment of corneal graft rejection, neovascularization, haze and herpetic stromal keratitis. These studies, corneal gene delivery systems and modes of administration, and considerations regarding the choice of animal species used are the focus of this review. Opportunities in the field of corneal gene therapy lie in expanding the array of corneal diseases investigated and in the implementation of recent designs of safer vectors with reduced immunogenicity and longer duration of gene expression.
Collapse
Affiliation(s)
- Eytan A Klausner
- Midwestern University Chicago College of Pharmacy, 555 31st Street, Downers Grove, IL 60515, United States.
| | | | | | | | | |
Collapse
|
24
|
Ofri R, Narfström K. Light at the end of the tunnel? Advances in the understanding and treatment of glaucoma and inherited retinal degeneration. Vet J 2007; 174:10-22. [PMID: 17307370 DOI: 10.1016/j.tvjl.2006.08.014] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2006] [Revised: 06/21/2006] [Accepted: 08/03/2006] [Indexed: 12/11/2022]
Abstract
Glaucoma and inherited retinal degeneration/dystrophy are leading causes of blindness in veterinary patients. Currently, there is no treatment for the loss of vision that characterizes both groups of diseases. However, this reality may soon change as recent advances in understanding of the disease processes allow researchers to develop new therapies aimed at preventing blindness and restoring vision to blind patients. Elucidating the molecular mechanisms of retinal ganglion cell death in glaucoma patients has led to the development of neuroprotective drugs which protect retinal cells and their function from the disastrous effects of elevated pressure. Identification of the genetic mutation responsible for inherited degenerations and dystrophies of the outer retina has enabled researchers using gene therapy to restore vision to blind dogs. Other patients may benefit from retinal transplantation, stem cell therapy, neuroprotective drugs, nutritional supplementation and even retinal prostheses. It is possible that soon it will be possible to restore sight to some blind patients.
Collapse
Affiliation(s)
- Ron Ofri
- Koret School of Veterinary Medicine, Hebrew University of Jerusalem, P.O. Box 12, 76100 Rehovot, Israel.
| | | |
Collapse
|
25
|
Sutanto EN, Zhang D, Lai YKY, Shen WY, Rakoczy PE. Potential use of cellular promoter(s) to target RPE in AAV-mediated delivery. Cellular promoters and RPE-targeting. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2007; 572:267-73. [PMID: 17249583 DOI: 10.1007/0-387-32442-9_37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Affiliation(s)
- Erika N Sutanto
- Centre for Ophthalmology and Visual Science, The University of Western Australia
| | | | | | | | | |
Collapse
|
26
|
Sutanto EN, Zhang D, Lai YKY, Shen WY, Rakoczy EP. Development and evaluation of the specificity of a cathepsin D proximal promoter in the eye. Curr Eye Res 2005; 30:53-61. [PMID: 15875365 DOI: 10.1080/02713680490894298] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
PURPOSE Recombinant adeno-associated virus (rAAV)-mediated gene delivery has emerged as a valuable tool for alternative treatment of ocular diseases. Cellular specificity of transgene expression could be influenced by either the viral capsid or the choice of promoter. The use of cellular promoter, cathepsin D (CatD) proximal promoter, and its potential for application in rAAV-based gene therapy are evaluated in this study. MATERIALS AND METHODS Different sizes of CatD proximal promoter fragments -769 to -1 (CD768), -366 to -1 (CD365), -253 to -1 (CD252), and -124 to -1 (CD123) were subcloned upstream of the green fluorescent protein (GFP) gene. The specificity and activity of the promoter were tested in vitro using human retinal pigment epithelium (RPE) cell lines (RPE51, D407), with the human fibroblast cell line (F2000) used as control. The promoter fragment that showed higher activity in RPE cells was chosen to generate rAAV vector based on AAV serotype 2. The ability of CatD promoter to target transgene expression to RPE in vivo was determined following subretinal delivery of rAAV particles into nonpigmented RCS/rdy+ rats. RESULTS In vitro studies showed that the proximal promoter fragment CD365 targeted high GFP expression in RPE cells. This fragment was then used to generate the AAV.CD365.gfp construct. It was shown in vivo that following subretinal injection, the CD365 fragment in AAV.CD365.gfp directed GFP expression preferentially into RPE cells. Relatively lower level of GFP expression was detected in the neuroretina. In contrast, injection of control virus (AAV.CMV.gfp) resulted in equal levels of transduction and fluorescence signal intensity in both the RPE and photoreceptor cells. CONCLUSIONS The results of our study demonstrate that the promoter fragment CD365 has the potential to target preferential gene expression in the RPE following subretinal injection in rAAV-mediated gene therapy.
Collapse
Affiliation(s)
- Erika N Sutanto
- Centre for Ophthalmology and Visual Science, The University of Western Australia, Nedlands, Western Australia 6009, Australia
| | | | | | | | | |
Collapse
|
27
|
Isenmann S, Schmeer C, Kretz A. How to keep injured CNS neurons viable—strategies for neuroprotection and gene transfer to retinal ganglion cells. Mol Cell Neurosci 2004; 26:1-16. [PMID: 15121174 DOI: 10.1016/j.mcn.2004.01.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2003] [Revised: 01/07/2004] [Accepted: 01/08/2004] [Indexed: 12/24/2022] Open
Affiliation(s)
- Stefan Isenmann
- Department of Neurology, University of Jena Medical School, 07747 Jena, Germany.
| | | | | |
Collapse
|
28
|
Tripathi BJ, Tripathi RC, Chen J, Gotsis S, Li J. Trabecular cell expression of fibronectin and MMP-3 is modulated by aqueous humor growth factors. Exp Eye Res 2004; 78:653-60. [PMID: 15106945 DOI: 10.1016/j.exer.2003.09.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We investigated the mRNA and protein expression of fibronectin and stromelysin-1 (matrix metalloproteinase-3, MMP-3) by trabecular cells treated with growth factors present in primary and secondary aqueous humors. Serum-deprived trabecular cells were incubated for 48 hr or 7 days in medium containing either primary or secondary aqueous humor growth factors or in serum-free medium. We extracted total RNA, performed reverse transcription-polymerase chain reaction using primer pairs for fibronectin, stromelysin-1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and quantified the products. We utilized Western blotting to detect and quantify fibronectin and stromelysin-1 protein. Compared to controls, expression of fibronectin mRNA by trabecular cells was increased by 50 and 100% after incubation in primary aqueous humor growth factors for 48 hr or 7 days, respectively, and 50 and 130% after incubation in secondary aqueous humor growth factors. Stromelysin-1 mRNA expression was decreased by 25 and 50% after incubation in primary aqueous humor growth factors for 48 hr or 7 days, respectively, and 80 and 85% after incubation for 48 hr or 7 days, respectively, in secondary aqueous humor growth factors. Fibronectin protein increased 3.5-fold and 6-fold after incubation for 48 hr with primary or secondary aqueous humor growth factors, respectively; after 7 days, the level increased 4- and 7-folds, respectively. Stromelysin-1 protein was not detectable by western blotting. The up-regulation of fibronectin mRNA by trabecular cells exposed to growth factors present in secondary aqueous humor augmented by the down-regulation of stromelysin-1 mRNA contributed to the accumulation of fibronectin. Our findings open the possibility that induction of stromelysin-1 gene expression in the trabecular meshwork of glaucomatous eyes could effectively reduce buildup of fibronectin in the aqueous outflow pathway to decrease outflow resistance in glaucomatous states of the eye.
Collapse
Affiliation(s)
- Brenda J Tripathi
- Department of Pathology and Microbiology, University of South Carolina School of Medicine, 6439 Garners Ferry Road, Columbia, SC 29209, USA.
| | | | | | | | | |
Collapse
|
29
|
Abstract
Vectors derived from adeno-associated viruses (AAV) represent a promising tool for retinal gene transfer in pre-clinical and clinical settings. AAV vectors efficiently transduce dividing and non-dividing cells, escape cellular immunity and result in long-non-term transduction. In addition, they may be targeted to specific retinal cell types by taking advantage of surface proteins from various AAV serotypes thus limiting transfer of therapeutic genes to those cells requiring correction. This review will provide an overview of the properties of AAV vectors followed by a detailed report of their use in retinal gene transfer for mendelian and non-mendelian disorders.
Collapse
Affiliation(s)
- Enrico M Surace
- Telethon Institute of Genetics and Medicine, Via P. Castellino 111, Naples 80131, Italy
| | | |
Collapse
|
30
|
Abstract
Gene therapy is envisioned as a potentially definitive treatment for a variety of diseases that have a genetic etiology. We reviewed trials of clinical gene therapy for nonmalignant, single-gene, and multifactorial disorders and infectious diseases, and found limited evidence suggesting that gene therapy may benefit patients who have severe, combined, immunodeficiency disorder; cystic fibrosis; coronary artery disease or peripheral arterial disease; or hemophilia. Effective gene therapy requires the targeted transfer of exogenous genetic material into human cells and the subsequent regulated expression of the corresponding gene product. Because no phase 3 randomized controlled trials have been completed that fulfill these criteria, it is difficult to correlate signs of clinical benefit with the administration of gene therapy in any disease. Additional clinical and basic research is needed to determine the future role of gene therapy.
Collapse
Affiliation(s)
- Thomas A Ratko
- Clinical Knowledge Services, University HealthSystem Consortium, Oak Brook, Illinois 60523-1890, USA.
| | | | | | | |
Collapse
|
31
|
Wen SF, Chen Z, Nery J, Faha B. Characterization of adenovirus p21 gene transfer, biodistribution, and immune response after local ocular delivery in New Zealand white rabbits. Exp Eye Res 2003; 77:355-65. [PMID: 12907168 DOI: 10.1016/s0014-4835(03)00122-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Previous studies suggest that local gene therapy with rAd-p21(WAF1/Cip-1) [. Arch. Ophthalmol. 120, (2002) 941-949] may provide an effective adjunctive anti-proliferative treatment to prevent glaucoma surgery failure. To further investigate rAd-p21 in this indication, we have characterized several parameters of local gene delivery to conjunctiva including, vector delivery and transgene expression in target tissue, inflammatory response, biodistribution to non-target tissues, and immune response. Quantitative PCR and RT-PCR assays were employed to evaluate rAd-p21 dissemination and gene transfer following a single subconjunctival injection. In target tissue, significant levels of rAd-p21 DNA were found in 6/6 animals 1 and 4 days after injection. rAd-p21 DNA and RNA could be detected in the un-injected contralateral eye but at levels that were 10000-100000 lower than in the injected eye. Expression of human p21 transgene in conjunctival fibroblasts was confirmed by immunohistochemistry. Biodistribution of rAd-p21 following subconjunctival injection was substantially limited to ocular tissue. In 1/6 rabbits, rAd-p21 DNA was found in whole blood, liver, and spleen at levels that were barely detectable. All non-target organs were negative on day 4. In contrast, in a rabbit injected intravenously as a positive control, all blood samples and tissues samples were positive. rAd-p21 delivery to conjunctiva followed by filtration surgery caused an early acute inflammatory response, which by day 14 was indistinguishable from placebo-treated eyes. Neutralizing anti-adenovirus antibodies were detected following administration of rAd-p21 to conjunctiva, however, vector delivery and transgene expression were unaffected in a subsequent administration to the contralateral eye in the same animal. These results show that local delivery to conjunctiva may be a suitable delivery mode for ocular gene therapy.
Collapse
Affiliation(s)
- S F Wen
- Canji Inc., 3525 John Hopkins Court, San Diego, CA 92121, USA
| | | | | | | |
Collapse
|
32
|
Surace EM, Auricchio A, Reich SJ, Rex T, Glover E, Pineles S, Tang W, O'Connor E, Lyubarsky A, Savchenko A, Pugh EN, Maguire AM, Wilson JM, Bennett J. Delivery of adeno-associated virus vectors to the fetal retina: impact of viral capsid proteins on retinal neuronal progenitor transduction. J Virol 2003; 77:7957-63. [PMID: 12829835 PMCID: PMC161923 DOI: 10.1128/jvi.77.14.7957-7963.2003] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
The development of fetal ocular gene transfer may be useful as a therapeutic tool for the prevention of retinal genetic disorders with congenital or early clinical manifestations. In this study we explored the neural progenitor transduction patterns of adeno-associated virus (AAV) vectors following delivery to the developing retina. Recombinant vectors with the same genome carrying the enhanced green fluorescent protein (EGFP) transgene packaged in capsids of differing serotypes (serotypes 1, 2, and 5, termed AAV2/1, AAV2/2, and AAV2/5, respectively) were created. Delivery of the AAV vectors during early retinal development resulted in efficient and stable transduction of retinal progenitors. Vector surface proteins and the developmental status of the retina profoundly affected viral tropism and transgene distribution. The procedure is not detrimental to retinal development and function and therefore provides a safe delivery vehicle for potential therapeutic applications and a means of assessing the mechanisms of retina development and disease.
Collapse
Affiliation(s)
- Enrico M Surace
- F. M. Kirby Center for Molecular Ophthalmology, Department of Ophthalmology, Scheie Eye Institute, 310 Stellar Chance Building, University of Pennsylvania, 422 Curie Boulevard, Philadelphia, PA 19104-6069, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Since the first reports describing the injection of recombinant adeno-associated viral (AAV) vectors in the murine eye, the advancement of the field has been enormous resulting in the correction of several animal models of retinal diseases. The recent development of "pseudotyped" AAV vectors with transduction characteristics that best fit the correction of specific retinal disease phenotypes and of sophisticated systems for tight regulation of gene expression expands on the potentiality of this delivery system for the eye.
Collapse
Affiliation(s)
- Alberto Auricchio
- Telethon Institute of Genetics and Medicine (TIGEM), Via P. Castellino 111, 80131, Napoli, Italy.
| |
Collapse
|
34
|
Liang FQ, Surace E, Dejneka NS, Maguire AM, Bennett J. Müller Cell Transduction by AAV2 in Normal and Degenerative Retinas. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2003; 533:439-45. [PMID: 15180296 DOI: 10.1007/978-1-4615-0067-4_56] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Affiliation(s)
- Fong-Qi Liang
- Retina Foundation of the Southwest, 9900 N. Central Expressway, Suite 400, Dallas, TX 75231, USA.
| | | | | | | | | |
Collapse
|
35
|
Abstract
We present an overview of the current status of basic science and translational research being applied to gene therapy for eye disease, focusing on diseases of the retina. We discuss the viral and nonviral methods being used to transfer genes to the retina and retinal pigment epithelium, and the advantages and disadvantages of each approach. We review the various genetic and somatic treatment strategies that are being used for genetically determined and acquired diseases of the retina, including gene replacement, gene silencing by ribozymes and antisense oligonucleotides, suicide gene therapy, antiapoptosis, and growth factor therapies. The rationales for the specific therapeutic approaches to each disease are discussed. Schematics of gene transfer methods and therapeutic approaches are presented together with a glossary of gene transfer terminology.
Collapse
Affiliation(s)
- Edward Chaum
- Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
| | | |
Collapse
|
36
|
Breuer DK, Yashar BM, Filippova E, Hiriyanna S, Lyons RH, Mears AJ, Asaye B, Acar C, Vervoort R, Wright AF, Musarella MA, Wheeler P, MacDonald I, Iannaccone A, Birch D, Hoffman DR, Fishman GA, Heckenlively JR, Jacobson SG, Sieving PA, Swaroop A. A comprehensive mutation analysis of RP2 and RPGR in a North American cohort of families with X-linked retinitis pigmentosa. Am J Hum Genet 2002; 70:1545-54. [PMID: 11992260 PMCID: PMC379141 DOI: 10.1086/340848] [Citation(s) in RCA: 181] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2002] [Accepted: 03/21/2002] [Indexed: 11/03/2022] Open
Abstract
X-linked retinitis pigmentosa (XLRP) is a clinically and genetically heterogeneous degenerative disease of the retina. At least five loci have been mapped for XLRP; of these, RP2 and RP3 account for 10%-20% and 70%-90% of genetically identifiable disease, respectively. However, mutations in the respective genes, RP2 and RPGR, were detected in only 10% and 20% of families with XLRP. Mutations in an alternatively spliced RPGR exon, ORF15, have recently been shown to account for 60% of XLRP in a European cohort of 47 families. We have performed, in a North American cohort of 234 families with RP, a comprehensive screen of the RP2 and RPGR (including ORF15) genes and their 5' upstream regions. Of these families, 91 (39%) show definitive X-linked inheritance, an additional 88 (38%) reveal a pattern consistent with X-linked disease, and the remaining 55 (23%) are simplex male patients with RP who had an early onset and/or severe disease. In agreement with the previous studies, we show that mutations in the RP2 gene and in the original 19 RPGR exons are detected in <10% and approximately 20% of XLRP probands, respectively. Our studies have revealed RPGR-ORF15 mutations in an additional 30% of 91 well-documented families with X-linked recessive inheritance and in 22% of the total 234 probands analyzed. We suggest that mutations in an as-yet-uncharacterized RPGR exon(s), intronic changes, or another gene in the region might be responsible for the disease in the remainder of this North American cohort. We also discuss the implications of our studies for genetic diagnosis, genotype-phenotype correlations, and gene-based therapy.
Collapse
Affiliation(s)
- Debra K. Breuer
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Beverly M. Yashar
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Elena Filippova
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Suja Hiriyanna
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Robert H. Lyons
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Alan J. Mears
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Bersabell Asaye
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Ceren Acar
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Raf Vervoort
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Alan F. Wright
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Maria A. Musarella
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Patricia Wheeler
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Ian MacDonald
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Alessandro Iannaccone
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - David Birch
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Dennis R. Hoffman
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Gerald A. Fishman
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - John R. Heckenlively
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Samuel G. Jacobson
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Paul A. Sieving
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| | - Anand Swaroop
- Departments of Human Genetics, Ophthalmology and Visual Sciences, and Biological Chemistry and Sequencing Core Facility, University of Michigan, Ann Arbor; Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn; New England Medical Center, Boston; Department of Ophthalmology, University of Alberta, Edmonton, Alberta; Department of Ophthalmology, University of Tennessee Health Science Center, Memphis; Retina Foundation of the Southwest, Dallas; University of Illinois at Chicago, Chicago; Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles; Scheie Eye Institute, University of Pennsylvania, Philadelphia; and National Eye Institute, Bethesda, MD
| |
Collapse
|
37
|
Natarajan K, Shepard LA, Chodosh J. The use of DNA array technology in studies of ocular viral pathogenesis. DNA Cell Biol 2002; 21:483-90. [PMID: 12167252 DOI: 10.1089/10445490260099782] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
DNA arrays can be used to simultaneously analyze the expression of hundreds of genes and permit systematic approaches to biological discovery with a potentially profound impact on genomics, pharmacogenomics, and proteomics. Microarrays have been used to study host-pathogen interactions, and recently this technology has been applied to investigate host-virus interactions. DNA arrays are used to monitor host alterations in several virus-induced cancers and upon infection with wild-type or modified viruses, or viral gene products. Alternatively, viral chips are used to characterize the transcriptional program of pathogenic viruses and in antiviral drug screening and drug resistance. With an aim to extend the use of this technology to ocular research, and specifically to study changes in host cell transcription in ocular adenovirus infection, we used a commercial array to compare adenovirus-infected human corneal cells to mock-infected cells. Of the 1176 genes analyzed, 72 genes associated with cell cycle regulation, apoptosis, oncogenesis, transcription, signaling, and inflammation were differentially regulated. In this review we summarize the use of DNA arrays in the study of viral infections and suggest potential uses of the technology in ocular viral pathogenesis research.
Collapse
Affiliation(s)
- K Natarajan
- Molecular Pathogenesis of Eye Infection Research Center, Dean A. McGee Eye Institute, Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
| | | | | |
Collapse
|
38
|
Rasmussen HS, Rasmussen CS, Durham RG, King CR, Wei L. Looking into anti-angiogenic gene therapies for disorders of the eye. Drug Discov Today 2001; 6:1171-1175. [PMID: 11700219 DOI: 10.1016/s1359-6446(01)02034-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Age-related macular degeneration (AMD) and proliferative diabetic retinopathy (DR) are the most common causes of visual impairment in the developed world. Because the key factor in AMD and DR is aberrant neovascularization in the retina (DR) or in the choroid (AMD), strategies to inhibit abnormal neovascularization represent a compelling therapeutic approach. Here we review various anti-angiogenic strategies for the treatment of ocular neovascular diseases with special emphasis on gene transfer as a way of achieving high, sustained concentrations of anti-angiogenic proteins in the back of the eye without concomitant systemic toxicity.
Collapse
|
39
|
Infectious neuroscience. Nat Rev Neurosci 2001. [DOI: 10.1038/35077542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
40
|
Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, Pearce-Kelling SE, Anand V, Zeng Y, Maguire AM, Jacobson SG, Hauswirth WW, Bennett J. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28:92-5. [PMID: 11326284 DOI: 10.1038/ng0501-92] [Citation(s) in RCA: 629] [Impact Index Per Article: 27.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Collapse
Affiliation(s)
- G M Acland
- James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Dejneka NS, Auricchio A, Maguire AM, Ye X, Gao GP, Wilson JM, Bennett J. Pharmacologically regulated gene expression in the retina following transduction with viral vectors. Gene Ther 2001; 8:442-6. [PMID: 11313822 DOI: 10.1038/sj.gt.3301413] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2000] [Accepted: 12/11/2000] [Indexed: 11/08/2022]
Abstract
The availability of inducible expression systems makes regulatable control of therapeutic proteins an attainable goal in gene therapy. We delivered tetracycline-inducible transgenes to the subretinal space using recombinant adenoviruses. Upon administration of doxycycline, we demonstrated reversible expression of green fluorescent protein in the retinal pigment epithelium as well as modulation of human growth hormone produced in the retina and secreted in the blood stream. This mode of delivery and regulation offers a unique way to evaluate gene function in the eye and represents a novel method for introducing therapeutic proteins into the retina.
Collapse
Affiliation(s)
- N S Dejneka
- Department of Ophthalmology, Scheie Eye Institute, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, PA 19104-6069, USA
| | | | | | | | | | | | | |
Collapse
|